Nippon Shinyaku Launches Orally Disintegrating Gaslon Tablets To Prolong Drug Lifecycle
This article was originally published in PharmAsia News
To prolong the lifecycle of gastritis and ulcer drug Gaslon (irsogladine), Nippon Shinyaku will launch an orally disintegrating tablet next November. company president Shigenobu Maekawa announced Nov.12. Maekawa said the company is also considering OD tablets for other drugs. Nippon Shinyaku has set three growth strategies: prolonging the lifecycle for current products, licensing products from others and in-house new drug development. This July, the company launched an OD tablet for benign prostatic hyperplasia drug Eviprostat (herbal extract) and saw sales for the new product grow 10 percent. Dysmenorrhea drugLunabell (norethisterone) was licensed and launched this July, and the company expects it to achieve ¥1 billion in sales by March 2009. (Click here for more - Japanese language
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.